# Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT03848754** · PHASE1 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 14 (actual)

## Conditions studied

- Relapsed Adult AML

## Interventions

- **DRUG:** Gemtuzumab Ozogamicin 3 mg/m^2
- **DRUG:** Gemtuzumab Ozogamicin 2 mg/m^2
- **DRUG:** Pracinostat - 45 mg
- **DRUG:** Pracinostat - 60 mg

## Key facts

- **NCT ID:** NCT03848754
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-24
- **Primary completion:** 2021-05-05
- **Final completion:** 2021-05-05
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2022-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03848754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03848754, "Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03848754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*